paroxetine has been researched along with methamphetamine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Caldecott-Hazard, S; Weissman, AD | 1 |
| Compton, DR; Mirshahi, T; Moore, KA; Poklis, A; Woodward, JJ | 1 |
| Bartel, RL; Goodhue, A; Smith, NB | 1 |
| Fleckenstein, AE; Hanson, GR; Haughey, HM; Metzger, RR | 1 |
| Antonuccio, DO; Kapadar, K; Kohlenberg, BS; Piasecki, MP; Steinagel, GM | 1 |
| Ishii, S; Ito, T; Kaneko, Y; Kashiwa, A; Nishikawa, T; Umino, A | 1 |
| Gross, G; Groth, I; Jongen-Relo, A; Rex, A; Wicke, KM | 1 |
| Hasegawa, R; Ikeda, K; Karasawa, J; Tamura, K; Yamamoto, H; Yamamoto, T; Yasumoto, S | 1 |
| Aungier, J; Cuesta, M; Morton, AJ; Ouk, K | 1 |
1 review(s) available for paroxetine and methamphetamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for paroxetine and methamphetamine
| Article | Year |
|---|---|
Penetrating the blind in a study of an SSRI.
Topics: Central Nervous System Stimulants; Double-Blind Method; Humans; Methamphetamine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders | 2002 |
12 other study(ies) available for paroxetine and methamphetamine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
In utero methamphetamine effects: I. Behavior and monoamine uptake sites in adult offspring.
Topics: Animals; Behavior, Animal; Biogenic Monoamines; Brain; Female; Male; Mazindol; Methamphetamine; Paroxetine; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley | 1993 |
Pharmacological characterization of BNMPA (alpha-benzyl-N-methylphenethylamine), an impurity of illicit methamphetamine synthesis.
Topics: Analysis of Variance; Animals; Brain; Carrier Proteins; Dopamine; Dose-Response Relationship, Drug; Electrophysiology; In Vitro Techniques; Male; Membranes; Methamphetamine; Mice; Paroxetine; Rats; Rats, Sprague-Dawley; Seizures; Selective Serotonin Reuptake Inhibitors | 1996 |
Exacerbation of psychosis by phenylpropanolamine.
Topics: Adult; Female; Hallucinations; Humans; Methamphetamine; Nasal Decongestants; Paranoid Disorders; Paroxetine; Perphenazine; Phenylpropanolamine; Psychoses, Substance-Induced; Recurrence; Substance-Related Disorders | 2000 |
The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia.
Topics: Animals; Antioxidants; Brain Chemistry; Carrier Proteins; Cell Membrane; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Hippocampus; Hyperthermia, Induced; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methamphetamine; Nerve Tissue Proteins; Paroxetine; Phenethylamines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptosomes | 2000 |
Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine.
Topics: Animals; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Fluoxetine; Head Movements; Locomotion; Methamphetamine; Mice; Paroxetine; Psychoses, Substance-Induced; Secondary Prevention; Selective Serotonin Reuptake Inhibitors | 2007 |
The guinea pig forced swim test as a new behavioral despair model to characterize potential antidepressants.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Clozapine; Desipramine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drugs, Investigational; Fluoxetine; Guinea Pigs; Injections, Intraperitoneal; Male; Methamphetamine; Monoamine Oxidase Inhibitors; Paroxetine; Piperidines; Selective Serotonin Reuptake Inhibitors; Swimming; Tranylcypromine | 2007 |
Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Topics: Animals; Dopamine; Fluoxetine; Fluvoxamine; Haloperidol; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Rats; Rats, Wistar; Reserpine; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Vesicular Monoamine Transport Proteins | 2009 |
Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease.
Topics: Animals; Central Nervous System Stimulants; Circadian Clocks; Circadian Rhythm; Cocaine; Disease Models, Animal; Female; Huntington Disease; Male; Methamphetamine; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Motor Activity; Paroxetine; Receptors, Dopamine; Selective Serotonin Reuptake Inhibitors; Serotonin; Synaptic Transmission; Vesicular Monoamine Transport Proteins | 2018 |